1057002-37-5

Basic information

• Product Name: 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one
• Synonyms: 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one
• CAS NO: 1057002-37-5
• Molecular Weight: 325.367
• Mol File: 1057002-37-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one(1057002-37-5)
• EPA Substance Registry System: 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one(1057002-37-5)

Safety Data

• Hazardous Substances Data: 1057002-37-5(Hazardous Substances Data)

Upstream product

• 495-69-2 Hippuric Acid 
• 3218-36-8 4-Phenylbenzaldehyde 

Downstream Products

• 1188994-55-9 C₂₈H₂₀N₂O 
• 1203704-89-5 C₂₈H₂₀N₂O₂ 
• 149818-98-4 methyl (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanoate 
• 91853-46-2 3-([1,1'-biphenyl]-4-yl)-2-oxopropanoic acid 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1573000-33-5 (R)-3-([1,1’-biphenyl]-4-yl)-2-aminopropan-1-ol hydrochloride 
• 170080-13-4 ([1,1’-biphenyl]-4-yl)alanine 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 1446104-51-3 (R)-2-benzoylamino-3-biphenyl-4-yl-propionic acid methyl ester 

Relevant articles and documents

NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES

The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.

SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES

The invention relates to a novel synthesis route towards R- biphenylalaninol and to the intermediates applied in this synthesis route. The process according to the invention and the intermediate compounds are useful in the synthesis of pharmaceutically ac

Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis

Disclosed are compounds of the Formula I and their use in a method of inhibiting the aggregation of amyloid proteins and in a method of imaging amyloid deposits.